Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Consolidated Net Income (2021 - 2026)

InMed Pharmaceuticals has reported Consolidated Net Income over the past 5 years, most recently at -$2.0 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 21.23% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$7.7 million, up 3.06%, while the annual FY2025 figure was -$8.2 million, 6.34% down from the prior year.
  • Consolidated Net Income for Q4 2025 was -$2.0 million at InMed Pharmaceuticals, down from -$1.7 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$336591.0 in Q2 2023 and troughed at -$7.9 million in Q2 2022.
  • A 5-year average of -$2.6 million and a median of -$2.1 million in 2022 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: skyrocketed 95.72% in 2023 and later crashed 473.57% in 2024.
  • Year by year, Consolidated Net Income stood at -$4.3 million in 2021, then skyrocketed by 51.01% to -$2.1 million in 2022, then increased by 29.55% to -$1.5 million in 2023, then crashed by 74.2% to -$2.6 million in 2024, then increased by 21.23% to -$2.0 million in 2025.
  • Business Quant data shows Consolidated Net Income for INM at -$2.0 million in Q4 2025, -$1.7 million in Q3 2025, and -$1.8 million in Q2 2025.